Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients

Exclusion Criteria

• •* Aged \<50 years
• •* Unable or unwilling to provide informed consent to participate in the trial
• •* Known allergy to or intolerance of the contents of the RZV vaccine
• •* No previous infection with VZV (chickenpox)
• •* History of primary immunodeficiency, documented vaccine hypo-responsiveness, or active immunosuppressive therapy
• •2. Population - Groups 2-4. Transplant recipients (n = 90)
• •* Aged \<18 years
• •* Unable or unwilling to provide informed consent to participate in the trial
• •* No previous infection with VZV (chickenpox)
• •* Known allergy to or intolerance of the contents of the RZV vaccine
• •* Current pregnancy
• •3. Population - Group 5. Other (n = 10)
• •* Aged \<18 years
• •* Unable or unwilling to provide informed consent to participate in the trial
• •* Known allergy to or intolerance of the contents of the RZV vaccine
• •* No previous infection with VZV (chickenpox)
• •* Known allergy to or intolerance of the contents of the RZV vaccine
• •* Current pregnancy
• •* History of primary immunodeficiency, documented vaccine hypo-responsiveness, or active immunosuppressive therapy
• •4. Population - Group 6. Dialysis group (n = 30)
• •Aged \<18 years
• •Unable or unwilling to provide informed consent to participate in the trial
• •Known allergy to or intolerance of the contents of the RZV vaccine
• •No previous infection with VZV (chickenpox)
• •Known allergy to or intolerance of the contents of the RZV vaccine
• •Current pregnancy
• •History of primary immunodeficiency or active immunosuppressive therapy